Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CALC by emailGet an email when CALC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CALC, unsubscribe in one click. Privacy
📣 What CALC Says Is Next
mid-2027 · “CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027.”
Company press release, Aug 11, 2026 · SEC filing
mid-2027 · “CalciMedica is advancing CM5480 for pulmonary hypertension, including PAH and PH-HFpEF, and anticipates submitting an IND in mid-2027.”
Company press release, Aug 11, 2026 · SEC filing
mid-2027 · “Pulmonary arterial hypertension: CalciMedica plans to conduct a Phase 1b proof-of-concept trial, with data anticipated in mid-2027.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CALC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CALC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.